Multi-symptom Relief and Improvement of Quality of Life – A Comparative Multicenter Trial on ColdZyme® Mouth Spray in Common Cold, Icelandic Medical Association conference, Jan 2019
The statistically significant results from the prospective, randomized parallel group study strongly support ColdZyme’s intended use of reducing the duration of colds, while also broadening its clinical benefit by showing that ColdZyme significantly reduces cold symptoms. ColdZyme alleviates sore throat, nasal congestion and headache, while improving quality of life and reducing the need for concurrent use of symptom-relieving medication for colds. A total of 267 subjects with naturally acquired colds were evaluated in the study, which was designed to investigate the ability of the Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21 Quality of life scale), the Jackson score, and two other scales for sore throat, to detect beneficial effects from ColdZyme when compared with a group that was not treated with ColdZyme. All four symptom scales showed statistically significantly improved effects when using ColdZyme compared with no treatment.
COLDPREV – A Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Study on ColdZyme® Mouth Spray against Rhinovirus-Induced Common Cold.OJRD, 2017, 7, 125–135
COLDPREV is a double-blind, placebo-controlled study of healthy volunteers who were inoculated (infected) with a cold virus. The results show a reduction of viral load (by over 99%), as well as a reduction in the number of days with common cold symptoms by over half (54%). Both results are statistically significant compared with placebo.
ColdZyme forms a protective barrier in the throat that deactivates five major common cold viruses, Swedish Otolaryngology Congress, Apr 2018
In 2018 the results of an in vitro study were announced showing that ColdZyme® has the ability to deactivate human coronavirus, one of the most common cold virus families. Along with the in vitro results from a study published in the fall of 2017, ColdZyme has been shown to be able to deactivate the majority of the viruses known to cause colds.
A medical device forming a protective barrier that deactivates four major common cold viruses. Virology Research Reviews, Issue 5, 2017
An in vitro study was carried out in 2017 by an independent accredited and certified laboratory. The study shows that ColdZyme is able to deactivate the majority of the most common viruses (rhinovirus, influenza virus, respiratory syncytial virus and adenovirus) that cause colds in humans. The in vitro study was based on standardized and validated methods developed to resemble the in vivo environment in the mouth and throat, where the virus attaches, invades the cells and causes the cold.
Pilot study: Does ColdZyme mouth spray reduce upper respiratory tract infection incidence or duration in endurance athletes?, 3rd European Otolaryngology-ENT Surgery Conference, Oct 2018, London, UK
In an investigator-initiated study conducted at the University of Kent, 35 endurance athletes were randomized to use ColdZyme or no treatment. The results showed significantly shorter duration of colds when using ColdZyme compared with endurance athletes in the untreated group. The results that were presented are in line with results from earlier studies on ColdZyme.
User Experience of ColdZyme Mouth Spray against Common Cold in Cold in Competitive athletes, OJRD, 8, 13-20, Apr 2018
ColdZyme can be a simple and practical method for competitive athletes to prevent or alleviate colds and thereby reduce undesired absence from training and competition.
Evaluation of ColdZyme Mouth Spray against Common Cold in Preschool Staff. OJRD, 7, 136–140, 2017
An observational study of preschool staff shows that the number of cold-related sick days decreased from 7.4 to 4.1 days over a 6-month period, compared with historical data for the same subjects. The difference was statistically significant.
Evaluation of ColdZyme Mouth Spray against Common Cold in Elderly Care Personnel. Open Journal of Respiratory Diseases, 7, 12–17, 2016
An observational study among elderly care personnel who used ColdZyme shows that the number of cold-related sick days decreased from 5.2 to 3.7 days over a 5-month period, compared with historical data. The difference was statistically significant. In all, 63% of those who developed a cold despite using ColdZyme experienced milder cold symptoms than during previously untreated colds.
Evaluation of ColdZyme® Mouth Spray on prevention of upper respiratory tract infections in a boy with primary immunodeficiency: a case report.J Med Case Rep. 2016;10(1):302
A case study of a young patient with primary immunodeficiency showed that ColdZyme reduced cold symptoms, as well as secondary microbial and fungal infections of the mouth and throat.
Enzymatica cares about your privacy and processes your personal data in accordance with the EU’s General Data Protection Regulation. For more information about how we handle your personal information, and what rights you have, please refer to our personal data processing document here.